Information  X 
Enter a valid email address

Qiagen N.V. (0H1Z)

  Print      Mail a friend       Annual reports

Monday 08 November, 2010

Qiagen N.V.

QIAGEN Reports Third Quarter 2010 Results




Qiagen N.V. /
QIAGEN Reports Third Quarter 2010 Results
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement. 

  * Net sales of $274.3 million in line with QIAGEN's quarterly expectations,
    8% organic net sales growth excluding swine flu-related products
  * Adjusted EPS of $0.25 ($0.27 CER) exceeds target, adjusted operating income
    margin exceeds 29% of net sales (30% CER)
  * QIAsymphony RGQ launch in Europe aims to expand position in profiling and
    personalized healthcare; Abbott pact provides access to key assays for North
    American markets


+---------------------------------------------------------------------------+
|QIAGEN's Third Quarter 2010                                                |
+---------------------------------------------------------------------------+
|in US$ millions, except per share information Q3 2010 Q3 2009        Growth|
+---------------------------------------------------------------------------+
|                                                                           |
|Net sales                                       274.3   259.7            6%|
|                                                                           |
|Net sales at constant exchange rates            279.1   259.7            7%|
|                                                                           |
|Net income, adjusted                             58.8    53.5           10%|
|                                                                           |
|EPS, adjusted (US$)                              0.25    0.26              |
|                                                                           |
+---------------------------------------------------------------------------+

 For information on the adjusted figures, please refer to the reconciliation
 table

 accompanying this release.


Venlo,  The Netherlands, November 8, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt
Prime Standard: QIA) today announced results of operations for the third quarter
and  the nine-month  period ended  September 30, 2010. Net  sales for  the third
quarter  of 2010 were  in line  with expectations  provided by  QIAGEN on August
10, 2010, while adjusted earnings per share exceeded those expectations.
"QIAGEN  delivered a solid performance in  the third quarter of 2010, meeting or
exceeding our guidance against the backdrop of challenging economic conditions,"
said  Peer Schatz, Chief  Executive Officer of  QIAGEN N.V. "While our molecular
diagnostics  franchise continues to grow rapidly  and gain share, the portion of
U.S.  sales in prevention  assays (approximately 20% of  sales and primarily HPV
tests)  has been exposed to declining doctors'  office visits. We have more than
offset this pressure through successful market conversion, resulting in steadily
increasing   penetration.   Our  successful  conversion  efforts  have  produced
sequential  quarterly and year-over-year growth in  this area despite a year-on-
year  decline in  visits of  up to  15%. Although we  believe a  reversal can be
expected,  this adverse trend has continued in the third quarter and will impact
our  full-year  sales  in  2010. At  the  same  time,  our  underlying  business
performance  remains strong, underscoring our strategic initiatives to expand in
molecular  diagnostics,  applied  testing,  pharma  and  academia. As we look to
2011, and  with current economic conditions  anticipated to continue, we believe
QIAGEN  is well-positioned to keep growing significantly faster than its markets
and make further progress toward global leadership in molecular technologies."
Third Quarter 2010 Results
Net  sales  in  the  third  quarter  of 2010 increased 6% to $274.3 million from
$259.7  million in  the same  quarter of  2009, and rose 7% at constant exchange
rates  (CER). Reported  operating income  for the  quarter declined  6% to $50.2
million from $53.4 million in the same quarter of 2009, while net income for the
2010 quarter  declined  3% to  $36.5  million  from  $37.7  million in the 2009
quarter.  Diluted earnings per  share for the  third quarter of 2010 declined to
$0.15  (based  on  239.0 million  weighted  average shares and share equivalents
outstanding)  from $0.18 in  the comparable 2009 period  (based on 208.3 million
weighted average shares and share equivalents outstanding).
Adjusted  operating income decreased 3% to $79.1 million in the third quarter of
2010 from $81.8 million in 2009, while adjusted net income rose 10% in the third
quarter  to  $58.8  million  from  $53.5  million in the comparable 2009 period.
Adjusted  diluted earnings per share  declined to $0.25 in  the third quarter of
2010 from $0.26 in 2009. Reconciliations of reported results to adjusted results
are included in the tables accompanying this release.
Nine-Month Period 2010 Results
Net  sales rose 11% to  $801.4 million in  the nine-month period ended September
30, 2010, from  $720.7 million  in the  same period  of 2009. Reported operating
income  of  $137.8  million  for  this  nine-month period was slightly above the
$137.3 million in the comparable 2009 period. Net income increased 16% to $108.0
million from $93.3 million in 2009, while diluted earnings per share of $0.45 in
the 2010 period were unchanged from the comparable 2009 period.
Adjusted  operating income in  the nine-month period  ended September 30, 2010,
increased  6% to $225.8 million from $212.7  million in 2009, while adjusted net
income  rose 13% to $160.7 million in the  first nine months of 2010 from $142.0
million  in  the  comparable  2009 period.  Adjusted  diluted earnings per share
decreased  to $0.67 per  share in the  first nine months  of 2010 from $0.69 per
share in the comparable 2009 period.
Results  for the third quarter and nine-month period of 2010 include the results
of  operations  from  recent  acquisitions,  notably  SABiosciences  Corporation
(acquired  in  December  2009) and  DxS  Ltd.  (acquired  in  September  2009).
Reconciliations  of  reported  results  determined  in accordance with generally
accepted  accounting principles (GAAP)  to adjusted results  are included in the
tables accompanying this release.
"Our  performance in the  third quarter of  2010, which faced a tough comparison
against  the  exceptional  contributions  of  swine  flu-related products to our
results  in 2009, reaffirms our  track record of  delivering organic growth with
improved  profitability," said Roland Sackers, Chief Financial Officer of QIAGEN
N.V.   "By   targeting   further  improvements  through  operational  excellence
initiatives  we have  improved our  adjusted operating  income margin during the
year,  exceeding 29% of net sales  in the third quarter  of 2010. We continue to
focus  on driving growth internally as well  as by leveraging our strong balance
sheet and cash flow."
Driving Growth and Strengthening Strategic Position in Molecular Diagnostics
QIAGEN  is in  an important  strategic phase,  driving significant  expansion in
molecular  diagnostics  -  prevention,  profiling,  personalized  healthcare and
point-of-need  testing - by leveraging its global leadership in sample and assay
technologies and making major investments in new products and market expansion.
Among  product categories,  consumables and  related revenues represented 88% of
net  sales in the third quarter of  2010 and grew 10% CER over the third quarter
of  2009. Instrumentation represented 12% of  net sales in  the third quarter of
2010, decreasing 5% CER from the comparable 2009 period.
All  customer classes had  improved performances in  the third quarter of 2010,
with  8% organic sales growth when  excluding significant one-time contributions
from  swine flu-related products in 2009. An additional six percentage points of
CER  sales growth was attributed to acquisitions made within the last 12 months.
(Total CER growth rates below are shown excluding swine flu-related sales):
Molecular  diagnostics (50% of  sales) advanced on  solid demand from end-market
customers  and expansion of the profiling assays portfolio (approximately 20% of
sales).  Sales rose 18% CER, which included five percentage points attributed to
acquisitions made within the last 12 months. In prevention assays (approximately
25% of sales), HPV (human papillomavirus) test screening and genotyping solution
sales  in the Americas have grown sequentially for three consecutive quarters in
2010, and  also  over  the  third  quarter  of  2009. QIAGEN's successful market
adoption   initiatives   continued  to  drive  sales,  more  than  offsetting  a
significant  decline in patient visits to doctors amid challenging U.S. economic
conditions.  In  personalized  healthcare  (approximately  5% of  sales), QIAGEN
formed  an  additional  partnership  with  an  undisclosed  major pharmaceutical
company to develop a molecular companion diagnostic.

Applied testing (7% of sales) benefited from portfolio expansion initiatives and
the  assay launch addressing new European standards in forensic testing as sales
rose  30% CER, which included seven percentage points attributed to acquisitions
made  within  the  last  12 months.  Further  growth is expected from the launch
during  the fourth quarter of  2010 of the first series  of food tests following
the  May  2010 acquisition  of  the  German  food  market business Institute for
Product Quality (ifp).

Pharma   (20%   of   sales)  enjoyed  sustained  demand  for  products  used  by
pharmaceutical  companies in development, particularly in Asia, while growth for
products  used in drug  discovery remained soft.  Sales grew 11% CER, with eight
percentage points attributed to acquisitions made within the last 12 months.

Academia  (23% of  sales) showed  a softer  performance in  the third quarter of
2010, although  trends indicate a solid market  outlook. Sales rose 5% CER, with
five  percentage  points  attributed  to  acquisitions  made within the last 12
months.
At  constant exchange rates, the Americas (53%  of sales), Europe (35% of sales)
and  Asia/Japan (11% of sales) all advanced  at robust double-digit rates in the
third  quarter of 2010 compared to the  same period in 2009 when excluding swine
flu-related product sales.
QIAGEN's  current  pipeline  is  exceptionally  strong,  providing a competitive
differentiation  and  key  growth  contributor.  A  key  2010 milestone  was the
European  launch in September  of QIAsymphony RGQ,  an automated modular testing
platform,  to  address  the  fast-growing  molecular  diagnostics  market and in
particular applications in profiling and personalized healthcare. It is the only
modular  system  that  covers  entire  laboratory  workflows from initial sample
preparation  to the final result, and  allows customers to run commercial assays
as well as to develop and conduct their own PCR-based assays.
QIAsymphony  RGQ,  with  approximately  10 assays  targeted  for U.S. regulatory
submissions,  also  forms  the  basis  of  an October 2010 agreement with Abbott
Laboratories  that is expected to significantly  strengthen the testing menus of
both  companies for automated  in vitro diagnostic  applications in the U.S. and
Canada.  The addition of Abbott's molecular  assays for HIV-1 and HCV (hepatitis
C)  will expand the molecular diagnostic menu of QIAsymphony RGQ to include some
of  the most frequently performed assays,  increasing the attractiveness of this
platform as a complete solution.
In  personalized healthcare,  the therascreen  KRAS assay,  which determines the
gene mutation status in patients with metastatic colon cancer, is expected to be
submitted  shortly for  U.S. regulatory  approval. This  would mark  another key
milestone   in   the   expansion  of  QIAGEN's  global  leadership  position  in
personalized  healthcare,  which  benefited  greatly  from  the  September 2009
acquisition  of DxS and subsequent integration that has been completed in 2010.
QIAGEN  offers approximately 20 molecular assays  in personalized healthcare and
has  a packed  development pipeline.  QIAGEN is  a clear  partner of  choice for
companion   diagnostics,   with  more  than  15 collaborations  under  way  with
pharmaceutical companies.
2010 outlook
For  2010, QIAGEN  is  reaffirming  its  full-year  earnings  guidance. Based on
foreign  exchange rates  as of  January 31, 2010, adjusted  diluted earnings per
share  of $0.91 - $0.92 are expected, which  is within the guidance range set by
QIAGEN  in  February  2010. The  target  for  full-year  2010 net sales has been
adjusted  to a new range of $1,090 - $1,105 million from $1,120 - $1,170 million
based  on  foreign  exchange  rates  as  of  January 31, 2010. This reflects the
ongoing  adverse impact of reduced U.S. patient  visits to doctors for HPV tests
in  its prevention portfolio  (impacting approximately 20% of  sales), which has
temporarily  dampened QIAGEN's growth that has  been driven by successful market
conversion initiatives.
Conference Call and Webcast Details
Detailed  information  on  QIAGEN's  business  and financial performance will be
presented  during a conference  call on Tuesday,  November 9, 2010, at 9:30 ET /
15:30 CET.  The corresponding presentation slides will be available for download
shortly  before the conference  call atwww.qiagen.com/goto/ConferenceCall, and a
webcast  is available at this  website. A replay will  also be made available on
this website.
Use of Adjusted Results
QIAGEN  has regularly reported adjusted results  to give additional insight into
its financial performance as well as considered results on a constant currencies
basis. Adjusted results should be considered in addition to the reported results
prepared in accordance with generally accepted accounting principles, but should
not  be considered as a substitute. The Company believes certain items should be
excluded  from  adjusted  results  when  they  are  outside  of its ongoing core
operations,   vary   significantly   from   period  to  period,  or  affect  the
comparability  of  results  with  the  Company's  competitors  and its own prior
periods. Reconciliations of reported results to adjusted results are included in
the tables accompanying this release.
About QIAGEN
QIAGEN  N.V., a Netherlands  holding company, is  the leading global provider of
sample  and  assay  technologies.  Sample  technologies  are used to isolate and
process  DNA, RNA and proteins from biological  samples such as blood or tissue.
Assay  technologies are used to make these isolated biomolecules visible. QIAGEN
has  developed and markets  more than 500 sample  and assay products  as well as
automated  solutions for such consumables. The  Company provides its products to
molecular  diagnostics  laboratories,  academic  researchers, pharmaceutical and
biotechnology  companies,  and  applied  testing  customers for purposes such as
forensics,  animal or food testing  and pharmaceutical process control. QIAGEN's
assay  technologies include one  of the broadest  panels of molecular diagnostic
tests  available worldwide. This panel includes  the first FDA-approved test for
human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs
nearly  3,600 people in  over 30 locations  worldwide. Further information about
QIAGEN can be found at

http://www.qiagen.com/.

Certain  of  the  statements  contained  in  this news release may be considered
forward-looking  statements  within  the  meaning  of  Section  27A of  the U.S.
Securities  Act  of  1933, as  amended,  and  Section 21E of the U.S. Securities
Exchange  Act of  1934, as amended.  To the  extent that  any of  the statements
contained  herein relating to QIAGEN's  products, markets, strategy or operating
results,  including  without  limitation  its  expected  operating  results, are
forward-looking,   such   statements  are  based  on  current  expectations  and
assumptions that involve a number of uncertainties and risks. Such uncertainties
and  risks include, but are not limited  to, risks associated with management of
growth   and   international  operations  (including  the  effects  of  currency
fluctuations,  regulatory processes and dependence on logistics), variability of
operating  results  and  allocations  between  business segments, the commercial
development of markets for our products in applied testing, personal healthcare,
clinical  research, proteomics,  women's health/HPV  testing, nucleic acid-based
molecular  diagnostics,  and  genetic  vaccination  and  gene  therapy, changing
relationships  with  customers,  suppliers  and strategic partners, competition,
rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's
products  (including fluctuations due to  general economic conditions, the level
and  timing of customers'  funding, budgets, and  other factors), our ability to
obtain  regulatory approval  of our  infectious disease  panels, difficulties in
successfully  adapting QIAGEN's  products to  integrated solutions and producing
such products, the ability of QIAGEN to identify and develop new products and to
differentiate  and  protect  its  products  from  competitors'  products, market
acceptance of QIAGEN's new products and the integration of acquired technologies
and  businesses. For  further information,  refer to  the discussions in reports
that  QIAGEN has filed with,  or furnished to, the  U.S. Securities and Exchange
Commission (SEC).
                                      ###
Contacts:
Investor Relations                     Public Relations

Dr. Solveigh Mähler  +49 2103 29 11710 Dr. Thomas Theuringer +49 2103 29 11826

Albert F. Fleury     +1 301 944 7028

e-mail:ir@qiagen.com                   e-mail:pr@qiagen.com


                              QIAGEN N.V.

              CONDENSED CONSOLIDATED STATEMENTS OF INCOME

                              (unaudited)



                                                         Three months

                                                        ended September
(in US$ thousands, except per share data)                     30,
                                                      ------------------

                                                        2010      2009
                                                      ------------------
Net sales                                              274,317   259,659

   Cost of sales                                        93,797    86,647
                                                      ------------------
Gross profit                                           180,520   173,012
                                                      ------------------

Operating expenses:

   Research and development                             30,980    26,747

   Sales and marketing                                  66,941    60,719

   General and administrative, integration and other    26,484    27,805

   Acquisition-related intangible amortization           5,880     4,387
                                                      ------------------
Total operating expenses                               130,285   119,658
                                                      ------------------


Income from operations                                  50,235    53,354
                                                      ------------------


Other income (expense):

   Interest income                                       1,227       678

   Interest expense                                    (6,980)   (7,405)

   Other income, net                                     2,374     2,692
                                                      ------------------
Total other expense                                    (3,379)   (4,035)
                                                      ------------------


Income before provision for income taxes                46,856    49,319

Provision for income taxes                              10,368    11,629
                                                      ------------------
Net income                                              36,488    37,690


   Weighted average number of diluted common shares    238,977   208,316


   Diluted net income per common share                  $ 0.15    $ 0.18



   Diluted net income per common share, adjusted        $ 0.25    $ 0.26


                               QIAGEN N.V.

               CONDENSED CONSOLIDATED STATEMENTS OF INCOME

                               (unaudited)



                                                           Nine months

                                                         ended September
(in US$ thousands, except per share data)                      30,
                                                       -------------------

                                                          2010      2009
                                                       -------------------
Net sales                                                801,399   720,748

    Cost of sales                                        274,861   241,787
                                                       -------------------
Gross profit                                             526,538   478,961
                                                       -------------------

Operating expenses:

 Research and development                                 92,001    77,340

 Sales and marketing                                     197,632   175,857

 General and administrative, integration and other        81,262    76,210

 Acquisition-related intangible amortization              17,878    12,289
                                                       -------------------
Total operating expenses                                 388,773   341,696
                                                       -------------------


Income from operations                                   137,765   137,265
                                                       -------------------


Other income (expense):

    Interest income                                        3,416     2,541

    Interest expense                                    (20,903)  (22,136)

    Other income, net                                      7,469     5,249
                                                       -------------------
Total other expense                                     (10,018)  (14,346)
                                                       -------------------


Income before provision for income taxes                 127,747   122,919

Provision for income taxes                                19,725    29,616
                                                       -------------------
Net income                                               108,022    93,303


     Weighted average number of diluted common shares    240,846   205,096


     Diluted net income per common share                  $ 0.45    $ 0.45



     Diluted net income per common share, adjusted        $ 0.67    $ 0.69


                                 QIAGEN N.V.

                    CONDENSED CONSOLIDATED BALANCE SHEETS



(in US$ thousands, except par value)              September 30,  December 31,

                                                      2010           2009
                                                 ----------------------------
Assets                                             (unaudited)


Current Assets:

 Cash and cash equivalents                              807,752       825,557

 Short-term investments                                  79,552        40,000

 Accounts receivable, net                               214,918       193,737

 Income taxes receivable                                  8,323        12,907

 Inventories, net                                       131,245       130,851

 Prepaid expenses and other                              74,863        96,893

 Deferred income taxes                                   34,909        33,525
                                                 ----------------------------
   Total current assets                               1,351,562     1,333,470
                                                 ----------------------------

Long-Term Assets:

 Property, plant and equipment, net                     336,746       317,467

 Goodwill                                             1,348,439     1,337,064

 Intangible assets, net                                 777,428        52,296

 Deferred income taxes                                   29,632        26,387

 Other assets                                            46,717        29,780
                                                 ----------------------------
   Total long-term assets                             2,538,962     2,462,994
                                                 ----------------------------
                                                 ----------------------------
  Total assets                                        3,890,524     3,796,464


Liabilities and Shareholders' Equity


Current Liabilities:

 Accounts payable                                        65,067        43,775

 Accrued and other liabilities                          210,474       248,699

 Income taxes payable                                    22,958        10,727

 Current portion of long-term debt                       75,427        50,000

 Current portion of capital lease obligations             3,555         3,417

 Deferred income taxes                                   17,674        18,912
                                                 ----------------------------
   Total current liabilities                            395,155       375,530
                                                 ----------------------------

Long-Term Liabilities:

 Long-term debt, net of current portion                 797,645       870,000

 Capital lease obligations, net of current
 portion                                                 24,440        27,554

 Deferred income taxes                                  206,606       212,690

 Other liabilities                                       36,209        19,521
                                                 ----------------------------
   Total long-term liabilities                        1,064,900     1,129,765
                                                 ----------------------------

Shareholders' Equity:

 Common shares, EUR .01 par value:

  Authorized--410,000 shares

  Issued and outstanding--232,832 shares

     in 2010 and 232,074 shares in 2009                   2,721         2,711

  Additional paid-in-capital                          1,642,473     1,622,733

  Retained earnings                                     723,601       615,579

  Accumulated other comprehensive income                 61,674        50,146
                                                 ----------------------------
   Total shareholders' equity                         2,430,469     2,291,169
                                                 ----------------------------
                                                 ----------------------------
  Total liabilities and shareholders' equity          3,890,524     3,796,464



                                  QIAGEN N.V.

                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES

                                  (unaudited)





                     Three months ended September 30, 2010

                       (in US$ millions, except EPS data)


                    Net     Gross   Operating Pre-tax  Income    Net    Diluted
                   Sales    Profit   Income   Income    Tax     Income    EPS*
                 ---------------------------------------------------------------
Reported results     274.3    180.5      50.2    46.9   (10.4)     36.5   $ 0.15

Adjustments:

 Business
 integration,
 acquisition
 related and
 restructuring
 costs and tax
 benefit from
 restructuring           -      0.2       3.8     3.7      2.7      6.4     0.03

 Purchased
 intangibles
 amortization            -     15.6      21.5    21.5    (7.6)     13.9     0.06

 Share-based
 compensation            -      0.2       3.6     3.6    (1.0)      2.6     0.01

 Income from
 divestitures and
 other
 acquisition
 related income          -        -         -   (0.6)        -    (0.6)        -
                 ---------------------------------------------------------------
 Total
 adjustments             -     16.0      28.9    28.2    (5.9)     22.3     0.10
                 ---------------------------------------------------------------
Adjusted results     274.3    196.5      79.1    75.1   (16.3)     58.8   $ 0.25


*  Using 239.0 M diluted shares



                     Three months ended September 30, 2009

                       (in US$ millions, except EPS data)


                    Net      Gross   Operating Pre-tax  Income    Net    Diluted
                   Sales    Profit    Income   Income    Tax     Income   EPS*
                 ---------------------------------------------------------------
Reported results     259.7     173.0      53,4    49.3   (11.6)     37.7  $ 0.18

Adjustments:

 Business
 integration,
 acquisition
 related and
 restructuring
 costs                   -       0.3       2.8     2.8    (0.9)      1.9    0.01

 Purchased
 intangibles
 amortization            -      13.1      17.5    17.5    (6.1)     11.4    0.06

 Share-based
 compensation            -       0.2       2.3     2.3    (0.7)      1.6    0.01

 Acquisition of
 DxS Ltd.                -       2.5       5.8     5.8    (1.7)      4.1    0.02

 Income from
 divestitures and
 other
 acquisition
 related income          -         -         -   (2.4)    (0.8)    (3.2)  (0.02)
                 ---------------------------------------------------------------
 Total
 adjustments             -      16.1      28.4    26.0   (10.2)     15.8    0.08
                 ---------------------------------------------------------------
Adjusted results     259.7     189.1      81.8    75.3   (21.8)     53.5  $ 0.26


*  Using 208.3 M diluted shares


Tables may have rounding differences.


                                  QIAGEN N.V.

                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES

                                  (unaudited)





                      Nine months ended September 30, 2010

                       (in US$ millions, except EPS data)


                    Net    Gross   Operating Pre-tax  Income    Net     Diluted
                   Sales   Profit   Income   Income    Tax     Income    EPS*
                 ---------------------------------------------------------------
Reported results    801.4    526.5     137.8   127.7   (19.7)    108.0   $  0.45

Adjustments:

 Business
 integration,
 acquisition
 related and
 restructuring
 costs and tax
 benefit from
 restructuring          -      0.9      14.2    14.2    (9.3)      4.9      0.02

 Purchased
 intangibles
 amortization           -     46.0      63.8    63.8   (22.5)     41.3      0.17

 Share-based
 compensation           -      0.7      10.0    10.0    (2.9)      7.1      0.03

 Income from
 divestitures and
 other
 acquisition
 related income         -        -         -   (0.6)        -    (0.6)         -
                 ---------------------------------------------------------------
 Total
 adjustments            -     47.6      88.0    87.4   (34.7)     52.7      0.22
                 ---------------------------------------------------------------
Adjusted results    801.4    574.1     225.8   215.1   (54.4)    160.7   $  0.67


*  Using 240.8 M diluted shares


                      Nine months ended September 30, 2009

                       (in US$ millions, except EPS data)



                    Net    Gross   Operating Pre-tax  Income    Net     Diluted
                   Sales   Profit   Income   Income    Tax     Income    EPS*
                 ---------------------------------------------------------------
Reported Results    720.7    479.0     137.3   122.9   (29.6)     93.3   $  0.45

Adjustments:

 Business
 integration,
 acquisition
 related and
 restructuring
 costs                  -      0.7      10.7    10.7    (3.4)      7.3      0.04

 Purchased
 intangible
 amortization           -     39.3      51.6    51.6   (18.0)     33.6      0.17

 Share-based
 compensation           -      0.7       7.3     7.3    (2.2)      5.1      0.02

 Acquisition of
 DxS Ltd.               -      2.5       5.8     5.8    (1.7)      4.1      0.02

 Income from
 divestitures and
 other
 acquisition
 related income         -        -         -   (2.4)    (0.8)    (3.2)    (0.02)

 Acquisition
 related write-
 off of prepaid
 expenses and
 other asset
 impairment             -        -         -     2.7    (0.9)      1.8      0.01
                 ---------------------------------------------------------------
 Total
 adjustments            -     43.2      75.4    75.7   (27.0)     48.7      0.24
                 ---------------------------------------------------------------
Adjusted results    720.7    522.2     212.7   198.6   (56.6)    142.0   $  0.69


*  Using 205.1 M diluted shares


Tables may have rounding differences.






[HUG#1460193]



 --- End of Message --- 

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands


Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Qiagen N.V. via Thomson Reuters ONE